The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

Healthcare has been running neck and neck with energy and consumer discretionary for the worst sector of 2025.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Here are four payer-related headlines in the last two weeks for ASCs to know. 1. Medical practices and hospitals saw claims denials increase and prior authorization denials decrease in 2024, according ...

Apple Inc (NASDAQ:AAPL) is accelerating development on smart glasses targeted for release in late 2026, marking a deeper push into AI-integrated consumer hardware, Bloomberg reported earlier. The ...